WO2007028117A3 - P8 as a marker for heart failure - Google Patents
P8 as a marker for heart failure Download PDFInfo
- Publication number
- WO2007028117A3 WO2007028117A3 PCT/US2006/034405 US2006034405W WO2007028117A3 WO 2007028117 A3 WO2007028117 A3 WO 2007028117A3 US 2006034405 W US2006034405 W US 2006034405W WO 2007028117 A3 WO2007028117 A3 WO 2007028117A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- heart failure
- marker
- diagnosis
- treatment
- present
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Electrotherapy Devices (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention is related to the diagnosis and treatment of p8-related conditions, particularly heart failure.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US71406705P | 2005-09-02 | 2005-09-02 | |
US60/714,067 | 2005-09-02 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007028117A2 WO2007028117A2 (en) | 2007-03-08 |
WO2007028117A3 true WO2007028117A3 (en) | 2007-10-18 |
Family
ID=37809631
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/034405 WO2007028117A2 (en) | 2005-09-02 | 2006-09-01 | P8 as a marker for heart failure |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2007028117A2 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002062205A2 (en) * | 2001-02-07 | 2002-08-15 | The General Hospital Corporation | Methods for diagnosing and treating heart disease |
US6852509B1 (en) * | 1996-10-29 | 2005-02-08 | Laurent Bracco | Anti-P53 single-chain antibody fragments and their uses |
-
2006
- 2006-09-01 WO PCT/US2006/034405 patent/WO2007028117A2/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6852509B1 (en) * | 1996-10-29 | 2005-02-08 | Laurent Bracco | Anti-P53 single-chain antibody fragments and their uses |
WO2002062205A2 (en) * | 2001-02-07 | 2002-08-15 | The General Hospital Corporation | Methods for diagnosing and treating heart disease |
Non-Patent Citations (4)
Title |
---|
IOVANNA: "Expression of the stress-associated p8 is a requisite for tumor development", INT. J. GASTROINTEST. CANCER, vol. 31, no. 1-3, 2002, pages 89 - 98 * |
NAKAMURA ET AL.: "Fas-Mediated Apoptosis in Adriamycin-Induced Cardiomyopathy in Rats", VIVO STUDY, vol. 102, August 2000 (2000-08-01), pages 572 - 578 * |
RAPISARDA ET AL.: "Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway", CANCER RESEARCH, vol. 62, August 2002 (2002-08-01), pages 4316 - 4324, XP002280284 * |
VASSEUR ET AL.: "p8-deficient fibroblasts grow more rapidly and are more resistant to adriamycin-induced apoptosis", ONCOGENE, vol. 21, March 2002 (2002-03-01), pages 1685 - 1694 * |
Also Published As
Publication number | Publication date |
---|---|
WO2007028117A2 (en) | 2007-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006089871A3 (en) | Diphenylurea derivatives useful as erg channel openers for the treatment of cardiac arrhythmias | |
WO2007018314A3 (en) | Therapeutic agent for diabetes | |
WO2008076046A8 (en) | Novel 2-amino-5, 5-diaryl-imidazol-4-ones | |
WO2009064388A3 (en) | Inhibitors of human methionine aminopeptidase 1 and methods of treating disorders | |
WO2007093627A3 (en) | Biocidal composition | |
WO2011028947A3 (en) | Heterocyclic compounds for the inhibition of pask | |
WO2007137071A3 (en) | Compositions of r(+) and s(-) pramipexole and methods of using the same | |
WO2011106322A3 (en) | Biomarkers for acute ischemic stroke | |
WO2003094856A3 (en) | 1l1rl-1 as a cardiovascular disease marker and therapeutic target | |
MY145439A (en) | Use of flibanserin for the treatment of pre-menopausal sexual desire disorders | |
WO2008006535A3 (en) | Use of a cationic colloidal preparation for the diagnosis and treatment of ocular diseases | |
UA94580C2 (en) | 39-desmethoxyrapamycin analogue with increased blood-brain barrier permeability for the treatment of a medical condition resulting from neural injury or disease | |
WO2009111633A3 (en) | Mercaptan and seleno-mercaptan compounds and methods of using them | |
WO2011039735A3 (en) | Compounds with ddx3 inhibitory activity and uses thereof | |
WO2008149353A3 (en) | Telomerase activating compounds and methods of use thereof | |
WO2006076370A3 (en) | Substituted cyclopentanes or cyclopentanones for the treatment of ocular hypertensive conditions | |
WO2009124330A3 (en) | Treatment of tumors | |
WO2007051785A3 (en) | Use of sdf-1 for the treatment and/or prevention of neurological diseases | |
WO2009074247A8 (en) | Novel 2-aryl-thiazole-4-carboxamide derivatives, production thereof, and use thereof as a medicament | |
WO2009124962A3 (en) | Sulfonamides | |
WO2009041663A1 (en) | Agent for prevention and/or treatment of skin diseases | |
WO2007144057A3 (en) | Antimicrobial carbon | |
WO2007038264A3 (en) | Gapr-1 methods | |
EA200900261A1 (en) | USE OF ESCIN | |
WO2007131907A3 (en) | 1h-indol-5-yl-piperazin-1-yl-methanone derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 06790155 Country of ref document: EP Kind code of ref document: A2 |